FDA Determines Regulatory Review Period for SURFAXIN Patent Extension

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for SURFAXIN, a human drug product, in response to a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.